AMT
24
-4
ESS
40
-2
PLD
32
-3
FAST
42
-2
MTB
41
-3
KO
42
-4
DHR
46
-3
SPG
43
-2
FITB
36
-2
SJM
9
-7
MCO
61
-7
SYF
62
-5
HST
34
2
NEE
34
-7
KLAC
58
-3
CNP
46
-3
HBAN
39
-9
RRC
60
2
CLX
65
-3
CMCSA
35
8
AMT
24
-4
ESS
40
-2
PLD
32
-3
FAST
42
-2
MTB
41
-3
KO
42
-4
DHR
46
-3
SPG
43
-2
FITB
36
-2
SJM
9
-7
MCO
61
-7
SYF
62
-5
HST
34
2
NEE
34
-7
KLAC
58
-3
CNP
46
-3
HBAN
39
-9
RRC
60
2
CLX
65
-3
CMCSA
35
8
Financhill
Back

Pacira BioSciences 10K Form

Buy
53

PCRX
Pacira BioSciences

Last Price:
$20.61
Seasonality Move:
6.99%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PCRX News And Ratings

See the #1 stock for the next 7 days that we like better than PCRX

PCRX Financial Statistics

Sales & Book Value

Annual Sales: $675M
Cash Flow: $49.8M
Price / Cash Flow: 5.81
Annual Sales: $16.24
Price / Book: 1.27

Profitability

EPS (TTM): -2.01000
Net Income (TTM): $-90.7M
Gross Margin: $490.3M
Return on Equity: -10.74%
Return on Assets: -5.77%

Pacira BioSciences Earnings Forecast

Key Pacira BioSciences Financial Ratios

  • The Gross Profit Margin over the past 16 years for PCRX is 72.64%.
  • The Selling, General & Administrative Expenses for PCRX have been equal to 39.92% of Gross Profit Margin.
  • The Research & Development expenses have been 11.30% of Revenue.
  • The Interest Expense is 41.26% of Operating Income.
  • The Net Earning history of PCRX is 6.22% of Total Revenues.
  • Per Share Earnings over the last 16 years have been positive in 8 years.

Pacira BioSciences Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PCRX
CUSIP: 695127
Website: pacira.com

Debt

Debt-to-Equity Ratio: 0.78
Current Ratio: 2.25
Quick Ratio: 1.81

Price-to-Earnings

Trailing P/E Ratio: 23.19
Forward P/E Ratio: 6.1

PCRX Technical Analysis vs Fundamental Analysis

Buy
53
Pacira BioSciences (PCRX) is a Buy

Is Pacira BioSciences a Buy or a Sell?